Work

Resistance to Second-Line Antibiotics in Mycoplasma pneumoniae Isolates From Children in East Asia

Year: 2026
Type: preprint
Abstract: Background: Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a therapeutic challenge in children, especially in East Asia. Tetracyclines and fluoroquinolones are alternatives when macrolides fail, but their in vitro resistance rates have not been synthesized by susceptibility-testing method. Methods: A unified search, with Chinese and English strings as block-for-block mirror images, covered six databases to September 1, 2026. Of 1,136 records, 700 remained after deduplication. Twenty pediatric studies were eligible; eleven tested cultured isolates by standardized dilution and formed the primary analysis of all isolates regardless of macrolide-resistance status, one contributed to sensitivity analysis, and eight were descriptive. Because all primary analyses observed zero events, results are pooled as 0.00% with exact upper 95% bounds. Results: No resistant isolate was observed for any second-line agent by each study's own criteria. Pooled resistance was 0.00% for tetracycline (n=2,353; upper bound 0.16%), levofloxacin (n=2,175; 0.17%), minocycline (n=1,545; 0.24%), moxifloxacin (n=805; 0.46%), and doxycycline (n=608; 0.60%); resistance was zero for both all-isolate and macrolide-resistant denominators. Interpretive criteria differed; a sensitivity analysis limited to CLSI M43-A studies gave the same result. One serology-based study without cultured isolates was not pooled. Conclusions: Across China and Japan (2002-2025), no cultured isolate resistant to tetracyclines or fluoroquinolones was observed. Absence of observed resistance is not evidence of absence: upper bounds (0.16%-0.60%) remain compatible with low-frequency resistance. Macrolides remain first-line; second-line agents retain activity, but standardized surveillance is needed.
Language: English
Subfield: Microbiology
Open Access status: green
OpenAlex ID: W7236602741
Cites: 46
Cited by:
Related to: 10